Books+ Search Results
Major Depressive Disorder Rethinking and Understanding Recent Discoveries
Title
Major Depressive Disorder [electronic resource] : Rethinking and Understanding Recent Discoveries / edited by Yong-Ku Kim.
ISBN
9789813360440
Edition
1st ed. 2021.
Publication
Singapore : Springer Singapore : Imprint: Springer, 2021.
Physical Description
1 online resource (XI, 563 p.) 30 illus., 22 illus. in color.
Local Notes
Access is available to the Yale community.
Access and use
Access restricted by licensing agreement.
Summary
This book reviews all aspects of major depressive disorder (MDD), casting light on its neurobiological underpinnings and describing the most recent advances in management. The book is divided into four sections, the first of which discusses MDD from a network science perspective, highlighting the alterations in functional and structural connectivity and presenting insights achieved through resting state functional MRI and the development of neuroimaging-based biomarkers. The second section examines important diagnostic and neurobiological issues, while the third considers the currently available specific treatments for MDD, including biofeedback, neurofeedback, cognitive behavioral therapy, acceptance and commitment therapy, neuromodulation therapy, psychodynamic therapy, and complementary and alternative medicine. A concluding section is devoted to promising emerging treatments, from novel psychopharmacological therapies through to virtual reality treatment, immunotherapy, biomarker-guided tailored therapy, and more. Written by leading experts from across the world, the book will be an excellent source of information for both researchers and practitioners.
Variant and related titles
Springer ENIN.
Other formats
Printed edition:
Printed edition:
Printed edition:
Format
Books / Online
Language
English
Added to Catalog
May 05, 2021
Series
Advances in Experimental Medicine and Biology, 1305
Contents
Section I. Re-thinking depression from a network perspective
Chapter 1. Phenotype network and brain structural covariance network of major depression
Chapter 2. Task MRI-based functional brain network of major depression
Chapter 3. White matter-based structural brain network of major depression
Chapter 4. The application of a machine learning-based brain MRI approach in major depression
Chapter 5. Resting state functional MRI in major depression
Chapter 6. Development of neuroimaging-based biomarkers in depressive disorder
Section II. Current diagnostic and neurobiological issues
Chapter 7. Challenges and strategies for current classifications of depressive disorders: proposal for future diagnostic standards
Chapter 8. Epigenetics: a missing link between early life stress and depression
Chapter 9. Glia- neuron communications and gut-brain axis in depression
Chapter 10. Apoptosis and proliferation markers in major depression
Chapter 11. A load to find clinically useful biomarkers for depression
Chapter 12. Pharmacogenomic tests for diagnosis and treatment prediction in depression
Section III. Current specific treatments for depression
Chapter 13. Biofeedback and neurofeedback for depression: a critical review
Chapter 14. Cognitive behavioral therapy and mindfulness based cognitive therapy for depressive disorders
Chapter 15. Acceptance Commitment Therapy (ACT) for major depressive disorder
Chapter 16. Neurostimulation therapies in depressive disorders
Chapter 17. Ketamine in major depression : New rapid antidepressant
Chapter 18. Psychodynamic therapy in depressive disorders
Chapter 19. Well-being therapy in depressive disorders
Chapter 20. Complementary and alternative medicine in the treatments of depressive disorders
Chapter 21. Current psychopharmacology algorithm for major depressive disorder
Section IV. Promising future treatments for depression
Chapter 22. Novel psychopharmacology for depressive disorders
Chapter 23. Cannabinoid agents for depressive disorders
Chapter 24. Virtual Reality for the treatment of depressive disorders
Chapter 25. Epigenetic Therapy in depressive disorders
Chapter 26. Induced pluripotent stem (iPS) cells technology: potential therapeutic targets for depression
Chapter 27. Vaccination and immunotherapy for major depression
Chapter 28. Psychedelic Medicines in major depression: progress and future challenges
Chapter 29. Precision Psychiatry: Biomarker guided Tailored Therapy for Effective Treatment and Prevention in major depression. .
Also listed under
SpringerLink (Online service)
Bookmark As
Citation
